Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

225 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development and Clinical Validation of Liquid Chromatography-Tandem Mass Spectrometry for Measuring Ruxolitinib in Steroid-Refractory Graft-Versus-Host Disease: A First Step Towards Optimized Treatment.
Redondo S, Costa M, Moreno-Martinez ME, Arguello-Tomas M, Riba M, Aso O, Iranzo E, Esquirol A, Sierra J, Briones J, Martino R, Zapico E, García-Cadenas I. Redondo S, et al. Among authors: briones j. Eur J Haematol. 2024 Nov 15. doi: 10.1111/ejh.14349. Online ahead of print. Eur J Haematol. 2024. PMID: 39545520
Sequence matters: Total body irradiation (TBI)-based myeloablative conditioning with post-transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus TBI.
Redondo S, García-Cadenas I, Vila A, Esquirol A, Portos JM, Novelli S, Saavedra S, Moreno C, Garrido A, Arguello-Tomas M, Oñate G, López-Pardo J, Caballero AC, Miqueleiz S, Briones J, Sierra J, Sancho G, Martino R. Redondo S, et al. Among authors: briones j. Eur J Haematol. 2023 Jul;111(1):146-153. doi: 10.1111/ejh.13978. Epub 2023 Apr 14. Eur J Haematol. 2023. PMID: 37058419
Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.
Redondo S, García-Cadenas I, Esquirol A, Portos JM, Iranzo E, Arguello-Tomas M, Saavedra S, Oñate G, Caballero AC, Garrido A, López J, Muntañola A, Paviglianiti A, Miqueleiz S, Sierra J, Briones J, Martino R. Redondo S, et al. Among authors: briones j. Eur J Haematol. 2024 Dec;113(6):776-787. doi: 10.1111/ejh.14294. Epub 2024 Aug 18. Eur J Haematol. 2024. PMID: 39155459
Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning.
Facchini L, Martino R, Ferrari A, Piñana JL, Valcárcel D, Barba P, Granell M, Delgado J, Briones J, Sureda A, Brunet S, Sierra J. Facchini L, et al. Among authors: briones j. Eur J Haematol. 2012 Jan;88(1):46-51. doi: 10.1111/j.1600-0609.2011.01724.x. Eur J Haematol. 2012. PMID: 22023368 Clinical Trial.
Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease.
García-Cadenas I, Valcárcel D, Martino R, Piñana JL, Novelli S, Esquirol A, Garrido A, Moreno ME, Granell M, Moreno C, Saavedra S, Briones J, Brunet S, Sierra J. García-Cadenas I, et al. Among authors: briones j. Biol Blood Marrow Transplant. 2013 Mar;19(3):435-9. doi: 10.1016/j.bbmt.2012.11.012. Epub 2012 Nov 20. Biol Blood Marrow Transplant. 2013. PMID: 23178634 Free article.
Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation.
García Cadenas I, Valcarcel D, Martino R, Piñana JL, Barba P, Novelli S, Esquirol A, Garrido A, Saavedra S, Granell M, Moreno C, Briones J, Brunet S, Sierra J. García Cadenas I, et al. Among authors: briones j. Mediators Inflamm. 2014;2014:620682. doi: 10.1155/2014/620682. Epub 2014 Jan 30. Mediators Inflamm. 2014. PMID: 24623962 Free PMC article.
Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges.
Redondo S, Esquirol A, Novelli S, Caballero AC, Garrido A, Oñate G, López J, Moreno C, Saavedra SD, Granell M, Briones J, Sierra J, Martino R, García-Cadenas I. Redondo S, et al. Among authors: briones j. Transplant Cell Ther. 2022 Jan;28(1):43.e1-43.e5. doi: 10.1016/j.jtct.2021.10.015. Epub 2021 Oct 29. Transplant Cell Ther. 2022. PMID: 34757054 Free article.
Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
García-Cadenas I, Redondo S, Esquirol A, Portos JM, Novelli S, Saavedra S, Moreno C, Garrido A, Oñate G, López J, Caballero AC, Miqueleiz S, Arguello-Tomas M, Briones J, Sierra J, Martino R. García-Cadenas I, et al. Among authors: briones j. Transplant Cell Ther. 2023 Jul;29(7):473.e1-473.e6. doi: 10.1016/j.jtct.2023.04.008. Epub 2023 Apr 20. Transplant Cell Ther. 2023. PMID: 37086849 Free article. Review.
225 results